alexa Ciliotherapy–New Opportunity for Targeted Therapy in Autosomal Dominant Polycystic Kidney Disease.
ISSN: 2157-7412

Journal of Genetic Syndromes & Gene Therapy
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Ciliotherapy–New Opportunity for Targeted Therapy in Autosomal Dominant Polycystic Kidney Disease.

Katarína Skalická* and László Kovács

Laboratory of Clinical and Molecular Genetics, 2nd Department of Pediatrics, Comenius University in Bratislava and University Children’s Hospital, Limbová, Bratislava, Slovakia

*Corresponding Author:
Katarína Skalická
Laboratory of Clinical and Molecular Genetics
2nd Department of Pediatrics
Comenius University in Bratislava and University Children’s Hospital
Limbová 1, 833 40, Bratislava, Slovakia
Tel: +421 (0) 2 593 711 873
E-mail: [email protected]

Received date October 07, 2016; Accepted date October 21, 2016; Published date October 28, 2016

Citation: Skalická K, Kovács L (2016) Ciliotherapy–New Opportunity for Targeted Therapy in Autosomal Dominant Polycystic Kidney Disease. J Genet Syndr Gene Ther 7:310. doi:10.4172/2157-7412.1000310

Copyright: © 2016 Skalická K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

 

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disease which affects nearly 12 million people in the world. Despite the intensive development of new treatment options, hemodialysis and renal replacement therapy remain the only effective treatment of the end-stage disease. However, recently there has been a significant progress in understanding the molecular pathogenesis of the disease, including the discovery of the role of the primary cilium. Recent studies have unequivocally confirmed that the change in the length of the primary cilium is an important trigger of pathological processes that results in the development and progression of ADPKD. The resumption of the primary cilium length by pharmacological regulation can stop cystic growth, prevent fibrosis, and improve kidney function. These results have opened a new era in the development of targeted drugs, so-called ciliotherapy. Early pre-clinical testing of new potential agents has brought promising results. However, there are many challenges in drug development and design of clinical trials in ADPKD, which must be overcome. This review summarized the state of knowledge about the key aspects of the primary cilium in pathogenesis of ADPKD and introduces the latest information on novel compounds that have a great potential in suppressing the development and progression of the disease.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords